Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
47 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Glomerulonephritis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Glomerulonephritis - Pipeline Review, H2 2014', provides an overview of the Glomerulonephritis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glomerulonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glomerulonephritis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glomerulonephritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glomerulonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glomerulonephritis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Glomerulonephritis Overview 6 Therapeutics Development 7 Pipeline Products for Glomerulonephritis - Overview 7 Pipeline Products for Glomerulonephritis - Comparative Analysis 8 Glomerulonephritis - Therapeutics under Development by Companies 9 Glomerulonephritis - Therapeutics under Investigation by Universities/Institutes 10 Glomerulonephritis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Glomerulonephritis - Products under Development by Companies 13 Glomerulonephritis - Products under Investigation by Universities/Institutes 14 Glomerulonephritis - Companies Involved in Therapeutics Development 15 Cyclacel Pharmaceuticals, Inc. 15 Toray Industries, Inc. 16 Hansa Medical AB 17 Pharmalink AB 18 Avexxin AS 19 FibroStatin SL 20 Glomerulonephritis - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 27 Drug Profiles 29 budesonide - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 CYC-065 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Endoglycosidase of Streptococcus pyogenes - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 AVX-235 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Peptide to Inhibit ETA and ETB for Rapidly Progressive Glomerulonephritis - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 GPBP Inhibitors - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Glomerulonephritis - Recent Pipeline Updates 38 Glomerulonephritis - Dormant Projects 40 Glomerulonephritis - Product Development Milestones 41 Featured News & Press Releases 41 Feb 19, 2014: Regulus Advances Orphan Disease Portfolio with Nomination of RG-012 as Clinical Development Candidate for the Treatment of Alport Syndrome 41 Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon 42 Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon 43 Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon 43 Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon 44 Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon 44 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables Number of Products under Development for Glomerulonephritis, H2 2014 7 Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Glomerulonephritis - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 15 Glomerulonephritis - Pipeline by Toray Industries, Inc., H2 2014 16 Glomerulonephritis - Pipeline by Hansa Medical AB, H2 2014 17 Glomerulonephritis - Pipeline by Pharmalink AB, H2 2014 18 Glomerulonephritis - Pipeline by Avexxin AS, H2 2014 19 Glomerulonephritis - Pipeline by FibroStatin SL, H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Number of Products by Stage and Target, H2 2014 23 Number of Products by Stage and Mechanism of Action, H2 2014 25 Number of Products by Stage and Route of Administration, H2 2014 26 Number of Products by Stage and Molecule Type, H2 2014 28 Glomerulonephritis Therapeutics - Recent Pipeline Updates, H2 2014 38 Glomerulonephritis - Dormant Projects, H2 2014 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
